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Summary: (Word count: 365) 91 
Background:  In laboratory animals, exposure to most general anaesthetics leads to neurotoxicity 92 
manifested by neuronal cell death, and abnormal behaviour and cognition.   Some, everal large 93 
human cohort studies demonstrate an association between general anaesthesia at a young age and 94 
subsequent neurodevelopmental deficits, but are prone to bias. Others have found no evidence 95 
for an association. We aimed to establish whether general anaesthesia in early infancy has an 96 
effect on neurodevelopmental outcomes in a randomised controlled trial (RCT).  97 
Methods: In this international assessor-masked equivalence RCT, infants less than 60 weeks’ 98 
postmenstrual age and born at greater than 26 weeks gestation undergoing inguinal 99 
herniorraphies without prior exposure to general anaesthesia or risk factors for neurologic injury 100 
were recruited. They were randomly assigned to receive either an awake-regional or sevoflurane-101 
based general anaesthetic. The primary outcome measure was the Wechsler Preschool and 102 
Primary Scale of Intelligence-Third Edition (WPPSI-III) Full Scale Intelligence Quotient (FSIQ) 103 
at 5 years of age. The primary analysis was as-per-protocol adjusted for gestational age at birth 104 
and country using multiple imputation to deal with missing data. An intention-to-treat analysis 105 
was also performed. A difference in means of five points was predefined as the clinical 106 
equivalence margin. This trial is registered with ANZCTR, number ACTRN12606000441516 107 
and ClinicalTrials.gov, number NCT007566000.  108 
Findings:  Between Feb 2007 and Jan 2013, 722 infants were randomised, 363 to the awake-109 
regional and 359 to general anaesthesia. The median duration of anaesthesia in the general 110 
anaesthetic group was 54 minutes. There were 74 protocol violations in the awake-regional 111 
group and 2 in the general anaesthesia group.  Primary outcome data for the as-per-protocol 112 
analysis were obtained from 205 children in the awake-regional group and 242 in the general 113 
anaesthesia group. The FSIQ score (mean [standard deviation (SD)]) was 99.08 (18.35) in the 114 
awake-regional group and 98.97 (19.66) in the general anaesthesia group, with a difference in 115 
means (awake-regional minus general anaesthesia) of 0.23, 95% Confidence Intervals -2.59 to 116 
3.06) showing strong evidence of equivalence. The results with the intention-to-treat analysis 117 
were similar to the as-per-protocol analysis.    118 
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Interpretation:  We found strong evidence that just under an hour of general anaesthesia in early 119 
infancy does not alter neurodevelopmental outcome compared to awake-regional anaesthesia in a 120 
predominantly male study population.  121 
Funding: National Institutes of Health (NIH) USA, Food and Drug Administration USA, 122 
Thrasher Research Fund, Australia National Health and Medical Research Council (NHMRC), 123 
Health Technologies Assessment-National Institute for Health Research UK. Australian and 124 
New Zealand College of Anaesthetists, Murdoch Children’s Research Institute, Canadian 125 
Institutes of Health Research, Canadian Anesthesiologists Society, Pfizer Canada, Italian 126 
Ministry of Health (RF-2011-02347532), Fonds NutsOhra,  the UK Clinical Research Network 127 
(UKCRN) and departmental sources. Britta S von Ungern-Sternberg is partly funded by the Perth 128 
Children’s Hospital Foundation, the Stan Perron Charitable Trust, and the Callahan Estate. 129 
 130 
  131 
7 
 
Research in context 132 
Evidence before this study 133 
We searched Medline and Cochrane controlled trials register (May 20, 2018) for original 134 
research and meta-analyses describing the association between anaesthetic exposure during 135 
childhood and neurodevelopmental outcome.  136 
The search terms used were “anesthesia” and “child development” or “anesthesia”  and “learning 137 
disorders”. No randomised trials were found except for the interim analysis of this trial published 138 
in the Lancet in 2016 which found equivalence in Bayley-III scores between infants exposed to 139 
either regional or general anaesthesia.  The majority of large cohort studies report an association 140 
between surgery before the age of four years and an increased risk for a later diagnosis of a 141 
behavioural problem or poorer academic attainment. In some of the studies the size of the 142 
increased risk is very small, in others it is only seen after multiple exposures. Several, but not all, 143 
of the cohort studies did not find an association with neurocognitive outcome as assessed by 144 
formal IQ testing. Weaknesses in these cohort studies include confounding, bias, heterogeneous 145 
populations at the time of exposure and heterogeneous outcome measures making interpretation 146 
and generalisation problematic.   147 
Added value of this study 148 
We report the 5 year neurodevelopmental outcome results for the GAS trial, the first randomised 149 
controlled trial designed to assess the effect of general anaesthesia in infancy on 150 
neurodevelopmental outcome.  We used the most reliable and validated measure of general 151 
intellectual ability, the Wechsler Preschool and Primary Scale of Intelligence-Third Edition  Full 152 
Scale IQ score and found strong evidence for equivalence between awake-regional and just less 153 
than one hour of general anaesthesia. No significant differences were seen in a range of other 154 
neurocognitive and behavioural measures.  155 
Implications of all the available evidence 156 
This randomised controlled trial provides strong evidence that an hour of exposure to a general 157 
anaesthetic during early infancy does not cause measureable neurocognitive or behavioural 158 
deficits at 5 years of age. These results are consistent with the MASK and PANDA cohort 159 
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studies. Nearly half the general anaesthetics in infancy are under an hour in duration and thus 160 
this study should allay some of the concerns generated by the preclinical data and previous 161 
cohort studies. This trial does not address the possibility that longer or repeated anaesthesia 162 
exposures in early childhood are detrimental. The trial was also conducted in a predominantly 163 
male population, and thus further research is needed which is directed specifically towards 164 
answering these questions relating to female sex, and multiple and prologed expsoures.    165 
 166 
 167 
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Introduction 169 
There are ongoing concerns about anaesthesia induced neurotoxicity for the developing brain.
1-2
  170 
In animal models, exposure to most general anaesthetics at a young age results in a range of 171 
morphologic changes.
3
  These exposed animals, including non-human primates, exhibit neuronal 172 
cell death, impaired neurogenesis, glial death and abnormal axon formation.
4-7
  Some animal 173 
models have also found that anaesthesia exposure in infancy is associated with altered 174 
behaviours including heightened emotional reactivity to threats, and impaired learning and 175 
memory formation persisting into early adulthood.
8,9
 Given the greater complexity of human 176 
development, it is unclear how these animal model findings translate to humans.  177 
In human cohort studies there is mixed and conflicting evidence for an association between 178 
exposure to anaesthesia in early childhood and a range of adverse neurodevelopmental 179 
outcomes.
10
  In light of the preclinical and clinical findings, anaesthesia societies in several 180 
countries have issued statements advising practitioners to consider delaying non-urgent surgery 181 
and to be prepared to discuss the issue with parents and the United States Food and Drug 182 
Administration has mandated warning labels on most general anaesthetics used in children. 
11,12
   183 
There have also been numerous calls for more definitive research to determine if anaesthetic 184 
exposure in early childhood has a clinically relevant impact on neurodevelopment in humans.
13,14
  185 
There are inherent difficulties in drawing any conclusions about causation from these cohort 186 
studies due to likely confounding, hence a randomised controlled trial would provide the 187 
strongest evidence for or against general anaesthesia causing adverse neurodevelopmental 188 
outcome.  189 
The neurodevelopmental outcome after general anaesthesia or awake-regional anaesthesia in 190 
infancy (GAS) trial was designed to answer the question of whether an exposure to general 191 
anaesthesia exposure in infants leads to clinically significant long term neurodevelopmental 192 
changes. A randomised trial to answer this question could only be performed on children 193 
undergoing a surgery for which either a volatile anaesthetic (which has been shown to cause 194 
injury and neurobehavioural deficits in animal models) or an awake-regional technique (which 195 
does not cause neuronal injury in animal models) can be used.
15
 Inguinal herniorraphy is one 196 
such surgery. An equivalence design was chosen as the primary aim was to determine if we 197 
10 
 
could exclude general anaesthesia causing clinically relevant neurotoxicity. Our hypothesis was 198 
that there would be no clinically important differences in neurodevelopmental outcome between 199 
general anesthesia and regional anesthesia. Such a finding of equivalence would result in: a) 200 
clinicians no longer subjecting children to the various risks of delaying surgery, and b) 201 
anaesthetists not avoiding general anaesthesia by using alternative, and potentially less well 202 
established anaesthetic techniques.   203 
The primary outcome for this trial (reported in this paper) is the Wechsler Preschool and Primary 204 
Scale of Intelligence (WPPSI-III) Full Scale Intelligent Quotient (FSIQ) measured at 5 years of 205 
age. A range of other secondary neurodevelopmental outcomes were also assessed at 5 years of 206 
age and are reported in this paper. Neurodevelopmental outcome at 2 years of age for the GAS 207 
trial was assessed using the Bayley Scales of Infant and Toddler Development III and has been 208 
previously published.
16
 There was no evidence for a difference in the scores between awake-209 
regional and general anaesthesia groups. An assessment at two years was regarded as an interim 210 
or secondary outcome as neurodevelopmental delays can be measured more accurately by 211 
assessments conducted at five years of age. Data relating to apnoea in the immediate post-212 
operative period, intra-operative blood pressure, regional anaesthesia and surgical outcomes have 213 
been published previously. 
17-20
   214 
  215 
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Methods  216 
Study design 217 
This was a multicentre, international, parallel group, randomised, assessor masked, controlled 218 
equivalence trial comparing neurodevelopmental outcome at 5 years of age after infants were 219 
randomised to receive awake-regional anaesthesia or general anaesthesia for inguinal 220 
herniorraphy. The trial was done in 28 hospitals in Australia, Italy, the US, the UK, Canada, the 221 
Netherlands and New Zealand. Institutional Review Board or Human Research Ethics 222 
Committee approval was obtained at each site and written informed consent was obtained from 223 
the infant’s parents or guardians. A summary of the protocol is available online.21 224 
The GAS trial is registered in Australia and New Zealand at ANZCTR: ID# 225 
ACTRN12606000441516 first registered on 16th October 2006; in the United States (US) at 226 
ClinicalTrials.gov: ID#: NCT00756600 first registered on 18th September 2008; and in the 227 
United Kingdom (UK) at UK Clinical Research Network (UKCRN) ID#: 6635 (ISRCTN ID#: 228 
12437565; MREC No: 07/S0709/20).  229 
The statistical analysis plan is available at ANZCTR (ID# ACTRN12606000441516). 230 
http://www.anzctr.org.au/AnzctrAttachments/1422-GAS%20SAP%205%20years.pdf. 231 
Participants  232 
Inclusion criteria were infants up to 60 weeks’ postmenstrual age, born at greater than 26 weeks’ 233 
gestation and scheduled for inguinal herniorraphy. Exclusion criteria were any contraindication 234 
for either anaesthetic technique, a history of congenital heart disease requiring surgery or 235 
pharmacotherapy, mechanical ventilation immediately before surgery, known chromosomal 236 
abnormalities or other known acquired or congenital abnormalities that might affect 237 
neurodevelopment, previous exposure to volatile general anaesthesia or benzodiazepines as a 238 
neonate or in the third trimester in utero, any known neurological injury such as cystic 239 
periventricular leukomalacia or grade three or four intraventricular haemorrhage, any social or 240 
geographical factor that might make follow-up difficult or having a primary language at home in 241 
a region where neurodevelopmental tests were not available in that language. We identified 242 
eligible infants from operating room schedules or at preadmission clinics and recruited in the 243 
clinic or in the preadmission areas of the operating floor. 244 
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Randomisation and Masking 245 
Infants were randomly assigned (1:1) to receive either general anaesthesia or awake-regional 246 
anaesthesia using a 24 hour web-based randomisation service managed by the Data Management 247 
and Analysis Centre, Department of Public Health, University of Adelaide, Australia. 248 
Randomisation was done in blocks of two or four in a computer generated random allocation 249 
sequence and stratified by site and gestational age at birth: 26-29 weeks and 6 days, 30-36 weeks 250 
and 6 days and greater than 37 weeks. The anaesthetist was aware of group allocation but 251 
individuals who administered neurodevelopmental assessments were not. Parents who asked 252 
about their infant’s group allocation were informed and told to mask this information from 253 
assessors. After assessments were completed, parents and assessors were asked if they were 254 
aware of group allocation.   255 
Procedures 256 
The awake-regional group received a spinal, caudal or combined caudal/spinal anaesthetic 257 
according to institutional preferences. Bupivacaine or levobupivacaine at a dose of 0.75 -1mg/kg 258 
was administered for spinal anaesthesia. Caudal anaesthesia was with 0.25% bupivacaine or 259 
levobupivacaine up to a total dose of 2.5 mg/kg. Several patients in the US in whom it was 260 
known that the surgery would take longer than one hour were also administered 3% 261 
chloroprocaine via a caudal catheter (loading bolus of 3% chloroprocaine 1 ml/kg over several 262 
minutes and then an infusion at 1-2 ml/kg/hr). Additional ilioinguinal and field blocks were 263 
performed according to surgical preference. Oral sucrose was given if the child was unsettled but 264 
no other pharmacological sedation was permitted. Infants who demonstrated agitation that was 265 
not resolved by oral sucrose or in whom the awake-regional anaesthetic was inadequate were 266 
treated with sevoflurane. The administration of sevoflurane, nitrous oxide or any other general 267 
anaesthetic in this group was considered a protocol violation.    268 
The general anaesthesia group received sevoflurane for induction and maintenance in a mix of 269 
air and oxygen. The concentration of sevoflurane, choice of airway device, ventilation technique 270 
and use of neuromuscular blocking agents were left to the preference of the anaesthetist. 271 
Supplemental opioids and nitrous oxide were not allowed but caudal, ilioinguinal-iliohypogastric 272 
or field block with bupivacaine were permitted to provide postoperative analgesia.     273 
13 
 
Both groups could also be given oral, rectal or intravenous paracetamol. Monitoring and 274 
recording were identical in both groups with heart rate, blood pressure, oxygen saturation, and 275 
expired sevoflurane concentrations (where applicable) every 5 minutes. In both groups 276 
intraoperative serum glucose values were measured after induction; rescue protocols for 277 
hypoglycaemia, hypotension and hypoxaemia were applied as appropriate.   278 
Outcome assessments 279 
Neuropsychological assessments were to be undertaken within 4 months of the child turning 5 280 
years of age. The total assessment time was estimated to take approximately 3 hours to complete 281 
and assessments were performed at each site by a child psychologist certified to conduct the 282 
tests. Quality control was maintained by a national coordinating psychologist. The primary 283 
outcome measure was that the Wechsler Preschool and Primary Scale of Intelligence-Third 284 
Edition Full Scale Intelligence Quotient WPPSI-III FSIQ score. Other The secondary outcome 285 
measures tests used were the Wechsler Preschool and Primary Scale of Intelligence-Third 286 
Edition (WPPSI-III), selected NEPSY-II subtests to assess attention and executive function, the 287 
Wechsler Individual Achievement Test Second Edition (WIAT-II) or the BVN (the Italian 288 
equivalent of the WIAT-II), selected subtests of the Children’s Memory Scale (CMS), the Global 289 
Executive Composite (GEC) of the Behavior Rating of Executive Function – Preschool Version 290 
(BRIEF-P), the Adaptive Behavioral Assessment System Second Edition (ABAS-II) and the 291 
Child Behaviour Checklist Caregiver Questionnaire (CBCL). Participatory tests were 292 
administered by the psychologist and a parent/caregiver completed the informant report 293 
questionnaires.  Parents were asked if their child had been diagnosed with cerebral palsy (CP), 294 
Autism Spectrum Disorder (ASD), Attention Deficit Hyperactivity Disorder (ADHD), or had 295 
any other neurodevelopmental issues. They were also asked if the child had received any 296 
neurodevelopmental interventions. Hearing or vision problems were also noted. Demographic 297 
data, family structure and medical history since randomisation were recorded, and a brief 298 
physical and neurologic examination was done for each patient. All these outcome measures 299 
were listed a prior in the protocol.  300 
All study data were sent to the Murdoch Children’s Research Institute in Melbourne, Australia.   301 
All data forms were checked by a research assistant not involved in primary data collection or 302 
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entry. Data on test forms that were not completed according to test manual instructions were 303 
rejected.    304 
An independent Data Safety Monitoring Committee met approximately every 6 months during 305 
recruitment.  Site visits were performed by the national coordinating teams for each country 306 
annually or biennially, and site visits at the national coordinating sites were done by principal 307 
investigators from other nations to check the validity of data. Summary data by allocation were 308 
presented to this committee.    309 
Statistical Analysis   310 
The study hypothesis was that the primary outcome, WPPSI-III FSIQ score at 5 years of age, is 311 
equivalent in infants who are anaesthetised for inguinal herniorraphy using awake-regional 312 
anaesthesia or general anaesthesia. Because this was an equivalence study, the outcome was 313 
analysed on an as-per-protocol basis to ensure a conservative estimate of the treatment effect in 314 
the direction of non-equivalence. In general it is best practice to analyse outcomes on an 315 
intention-to-treat (ITT) basis where all participants are included according to their randomised 316 
allocation and issues of selection bias are avoided. In this study there were unavoidable protocol 317 
violations, the majority of which were in babies allocated to regional anaesthesia who had some 318 
exposure to general anaesthesia particularly if the awake-regional anaesthesia failed. If all infants 319 
were analysed according to their randomised allocation in an ITT analysis, this switching from 320 
one randomised treatment to the other could dilute the potential effect of general anaesthesia and 321 
thus bias the trial towards equivalence.
22
   322 
Equivalence was defined a priori as the 95% confidence interval (CI) of the difference in means 323 
of the FSIQ lying within minus five and plus five IQ points. Intention-to-treat analyses were also 324 
planned. All confidence intervals are two-sided 325 
The sample size was based on the primary outcome; the 5-year follow-up WPPSI-III FSIQ score. 326 
Assuming an expected difference of one standardised score point, a standard deviation of 15,  327 
and a 90% chance that a 95% CI will exclude a difference of more than five points (the largest 328 
difference acceptable to show equivalence), the trial would need 598 infants. The sample size 329 
formula used was based on approximations to the normal distribution, and used a two one-sided 330 
15 
 
test (TOST) procedure. Enrolling roughly 720 participants would allow for 10% loss to follow-331 
up and 10% with a major protocol violation.  332 
We used multiple imputation under a multivariate normal distribution to impute missing outcome 333 
data in the primary analysis of all outcomes, with a sensitivity analysis on complete cases only. 334 
The mi impute mvn statement in Stata was used to do the multiple imputations.  The variables 335 
used in the multiple imputation models included baseline, post-randomisation, 2 year cognitive 336 
variables and 5 year outcome variables.  The following prespecified variables were used as 337 
possible predictor variables within the imputation approach (since most of these variables also 338 
have missingness, they were also imputed where necessary):  Baseline: anaesthesia group, 339 
country, sex, gestational age at birth, birth weight, mother received antenatal steroids, mother’s 340 
education, maternal age < 21; Surgery:  need for fluid bolus for hypotension, duration of surgery, 341 
significant postoperative apnoea, age at surgery; 2 years: composite cognitive, language, motor 342 
and social-emotional score of the Bayley scales of Infant and Toddler Development-Third 343 
Edition, any additional anaesthetic exposures since the inguinal herniorraphy, any interventions 344 
for neurodevelopmental problems, any other neurological abnormality; 5 years: WPPSI-III FSIQ, 345 
any chronic illness, any additional anaesthetic exposures since the inguinal herniorraphy, total 346 
length of any readmission to hospital, cerebral palsy, any interventions for neurodevelopmental 347 
problems, any other neurological abnormality. With many missing observations these multiple 348 
imputation models did not always converge, in which case applicable variables were not 349 
included in order to ensure convergence of models. The variables used in the analysis model 350 
were always included in the imputation models.  351 
For all continuous outcomes, linear regression was used with the factor variables anaesthesia arm 352 
(factor levels: awake regional and general anaesthesia), gestational age at birth and country as 353 
fixed effects. Adjusted mean differences are presented with 95% Cis. 354 
All binary outcomes were analysed using generalised linear models (GLM) with binomial link 355 
function in order to enable estimation of risk ratios, adjusting for the same factors as for the 356 
linear regression. Risk ratios are presented with 95% CIs. 357 
All following subgroup analyses were pre-specified in the statistical analysis plan: country, 358 
duration of surgery greater or less than 120 minutes, and age at surgery (greater or less than 70 359 
days). A subgroup analysis by ex-term versus ex-preterm (born at <37 weeks gestation) was also 360 
16 
 
performed post hoc. P-values for the interactions are presented along with subgroup treatment 361 
effect estimates and 95% CIs. All analyses were carried out in Stata (version 14.2).  362 
Role of the funders 363 
The funders of this study had no role in data collection, analysis, interpretation, writing this 364 
manuscript or the decision to submit this manuscript. AG has complete access to the data. All 365 
other authors have access to the data on request. All authors were responsible for the decision to 366 
submit this manuscript.  367 
  368 
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Results 369 
Between 9
th
 February 2007 and 31
st
 January 2013, 722 infants were recruited and randomised at 370 
28 centres in 7 countries (table 1). There were two misrandomisations and one family withdrew 371 
consent after randomisation and before surgery. This left 361 children in the intention-to-treat 372 
analysis for the awake-regional group and 358 children in the general anaesthesia group [Figure 373 
1]. Table 2 summarises baseline data for each group and Table 3 summarises demographic data 374 
at the 5 year assessment. There were 74 protocol violations in the awake-regional group (the 375 
surgeries for 5 children were cancelled and 69 children received some sevoflurane or other 376 
general anaesthetic agent) and two protocol violations in the general anaesthesia group (surgery 377 
cancelled). The only adverse events during the anaesthesia were related to respiratory 378 
complications. These have been previously described in full in a separate publication. 
17
 There 379 
were no other adverse events in either group. The frequency of hypotension has also been 380 
described elsewhere. 
18
   381 
The 5 year follow up assessments were conducted from 13
th
 March 2012 to 27
th
 April 2018. In 382 
total 91 families were lost to follow up in the awake-regional group and 97 in the general 383 
anaesthesia group; a follow up rate of 74%. Of those that attended for assessment the WPPSI-III 384 
FSIQ was complete for 205 in the awake-regional group and 242 in the general anaesthesia 385 
group. Numbers lost to follow up and numbers of complete case assessments are listed for each 386 
sit in table 1.    387 
Table 4 summarises the results for the individually administered tests for each group and the 388 
differences in means between groups. There was strong evidence for equivalence of the WPSSI-389 
III FSIQ means between awake-regional and general anaesthesia groups in both the as-per-390 
protocol and intention-to-treat analyses using multiple imputation to account for missing data 391 
(adjusted mean difference for awake-regional minus general anaesthesia 0.23, 95% CI -2.59 to 392 
3.06 for as-per-protocol analysis; and 0.16, -2.45 to 2.78 for intention-to-treat analyses). There 393 
was also evidence for equivalence in the complete cases analyses (adjusted mean difference for 394 
awake-regional minus general anaesthesia 0.628, 95% CI -2.093 to 3.349 for as-per-protocol 395 
analysis; and 0.266, -2.268 to 2.799 for intention-to-treat analyses). In all these analyses the 396 
upper and lower bounds of the 95% confidence intervals were well within the prespecified 5 397 
point equivalence margin. There was also evidence for equivalence of the verbal, performance 398 
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and processing speed composite scores of the WPPSI-III, with the 95% confidence intervals 399 
around the differences in means again within 5 points in as-per-protocol, intention-to-treat, 400 
multiple imputation and complete case analyses. For all the other individually administered 401 
secondary outcomes (Table 4) and parent or caregiver reported outcomes (Table 5) none of the 402 
95% confidence intervals around the differences in means were either entirely above or below 403 
zero in any of the analyses. Although an equivalence margin was not prespecified for these 404 
secondary outcomes a reasonable assumption of equivalence could be made, as the upper and 405 
lower bounds of all 95% confidence intervals were within a third of a standard deviation for all 406 
analyses (the equivalence limit prespecified for the primary outcome).   407 
Some of the NEPSY-II subscales had large numbers of missing data and the standard deviations 408 
were very large with the multiple imputation models.  This is because the correlations of the 409 
variables included in the multiple imputation model with the outcome variable were low, leading 410 
to not much information being recovered using the multiple imputations, while additional noise 411 
was added.  412 
Table 6 gives the proportion of children in each group that were reported by a parent to have 413 
been diagnosed with a neurodevelopmental disorder and the risk ratio for both as-per-protocol 414 
and intention-to-treat analyses. No evidence for any differences was found, with the 95% 415 
confidence intervals of all risk ratios crossing 1. However the low event rates limit the inferences 416 
that can be drawn regarding equivalence.   417 
The subgroup analyses for the primary outcome are reported in Table 7. These analyses suggest 418 
that the differences between groups were similar by age of exposure, and prematurity.  Small 419 
sample sizes in some of the countries made it inconclusive to interpret country differences in the 420 
results. Duration of exposure was not analysed as no children had exposures longer than 120 421 
minutes. The p-value evaluating treatment by country interaction was 0.0496 for the complete 422 
case analysis and 0.0643 for the multiple imputation analysis; providing evidence of 423 
heterogeneity of the results by country.   424 
In Table 8, the characteristics of children who attended the 5 year follow up are compared to the 425 
baseline data of the randomised population and the 2 year outcome data for those who attended 426 
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the 2 year follow up. Table 9 demonstrates the unmasking of group allocation for children who 427 
attended the 5 year follow up. 428 
   429 
 430 
  431 
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Discussion:  432 
In this randomised trial we found strong evidence for equivalence in full scale IQ measured at 433 
five years of age between children anaesthetised with awake-regional and general anaesthesia for 434 
inguinal herniorraphy in infancy. In a range of other neuropsychological tests evidence of 435 
equivalence may also be reasonably assumed as the 95% CI around the differences in means fell 436 
within one third of a standard deviation. These results are consistent with the previously reported 437 
2 year outcomes of the GAS trial using the Bayley-III.
16
  438 
The primary outcome was determined at 5 years of age as there is robust evidence for the 439 
emergence of the unitary construct of ‘general intelligence’ and for the individual stability of that 440 
construct from middle childhood until adulthood.  IQ testing in children around the age 5-6 years 441 
has a strong correlation with adult IQ.
23
 It has also been shown that IQ aged 5 years is highly 442 
predictive of later Maths ability, and that higher IQ in childhood positively predicts a range of 443 
benefits in academic, economic and health outcomes across the lifespan.
24
 The WPPSI-III is a 444 
well-validated, standardised, reliable test for assessing IQ in young children. 445 
The IQ, as a measure of intelligence, has significant implications for social-emotional, 446 
educational and vocational outcomes throughout the lifespan. The WPPSI-III is an 447 
individualised, standardised, reliable and valid test for assessing IQ in young children. The 448 
WPPSI-III FSIQ was set as the primary outcome not only due to its strong psychometric 449 
properties and predictive potential, but also due to the preclinical data. The widespread cortical 450 
damage seen in preclinical models would most likely result in a global decline in function. This 451 
would be best identified by a measure of general intellectual function such as the WPPSI-III. 452 
Secondary outcome measures were selected to assess a broad range of cognitive domains that 453 
could potentially be impacted based on known vulnerabilities of the developing brain and in 454 
response to early animal and human studies. In choosing the tests a number of factors were 455 
considered: previous studies found deficits in both hippocampal and non-hippocampal memory; 456 
deficits that arise from damage to systems that subserve specific skills are spread through various 457 
regions of the brain and are particularly vulnerable to neurological insult (i.e. attention, 458 
information processing and executive function); there is a  possibility of a cumulative effect of 459 
subtle individual or multiple deficits on skill development such as visuo-motor integration, 460 
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reading, spelling and arithmetic; and there is previous evidence for social and emotional deficits. 461 
Specific individually administered tests and informant report measures were selected from 462 
readily available standardised tests in common clinical use with documented reliability and 463 
validity statistics for use in this age group.  464 
Several previous cohort studies have sought to identify associations between anaesthesia 465 
exposure in early childhood and a range of neurodevelopmental outcomes. The PANDA study 466 
was an ambidirectional cohort study that compared neurodevelopmental outcome between 467 
children that had previous inguinal herniorraphy and their unexposed siblings using a range of 468 
neuropsychological tests performed at 8-15 years of age.
25
 This study found no evidence of 469 
group differences in IQ scores, or scores on a range of other tests of neurocognitive function and 470 
behaviour.  Similarly, the MASK cohort study found no evidence for differences between test 471 
scores between children that had a single anaesthetic compared to those that had no previous 472 
anaesthetics, although children that had multiple anaesthetics did have an increased risk of 473 
deficits in processing speed and fine motor outcomes, and parents reported increased problems 474 
related to executive function, behaviour and reading.
26
  Other cohort studies have found evidence 475 
for an association between anaesthesia exposure and cognitive, memory, listening 476 
comprehension and language deficits.
27-30
  477 
Several other large population-based data linkage studies have found evidence for an association 478 
between anaesthesia in early childhood and a very small decrease in performance in school 479 
grades or school readiness tests.
31-34
  There is mixed evidence in cohort studies for an association 480 
between anaesthesia in early childhood and a subsequent diagnosis of ADHD or other learning 481 
disability.
35-42
  It is plausible that there may be an increased the risk of these diagnoses without 482 
an increased the risk of worse outcomes in neurocognitive testing, however other confounding 483 
factors are also a possible explanation for these observed associations. The GAS trial found no 484 
evidence for an increased risk of behavioural disorders such as ASD or ADHD, however the 485 
diagnosis of ADHD and learning disability is typically made in older children, and the low event 486 
rate and hence limited power reduced our ability to draw a definitive conclusion.   487 
In all these cohort studies any association found between exposure and poor outcome may be 488 
explained by confounding. Children have anaesthesia because they are having surgery or 489 
invasive investigations. The condition warranting the procedure may itself be associated with 490 
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increased risk of adverse neurodevelopmental outcome. Similarly children with pre-existing but 491 
as yet undiagnosed behavioural problems may be at greater risk of needing the procedure. Lastly 492 
perioperative factors other than anaesthesia may also increase the risk of poor 493 
neurodevelopmental outcome.  In most studies, attempts are made to limit the effects of known 494 
confounders through patient selection, matching and adjustments in the analysis but the potential 495 
influence of confounding can never be eliminated. The GAS trial is the only randomised trial so 496 
far that assesses the impact of anaesthesia on neurodevelopment and thus provides the strongest 497 
human evidence.  498 
Several previous cohort studies have found more evidence for a detrimental effect after multiple 499 
exposures compared to a single exposure. In the GAS trial a substantial number of children had 500 
subsequent anaesthetics. The number of children having subsequent anaesthetics was well 501 
balanced between arms and thus the occurrence of subsequent anaesthetics is unlikely to 502 
influence or bias the results of this trial.   503 
There was weak evidence for an interaction between country and treatment. The reason for this is 504 
not immediately apparent and given the marginal level of evidence this finding should be 505 
interpreted with caution.  506 
Despite careful selection of patients, an awake-regional technique is not always adequate for 507 
herniorraphy. Thus a substantial number of children in the awake-regional group had some 508 
exposure to general anaesthetics. These children were excluded in the as-per-protocol analysis. 509 
The lack of any substantive difference between the as-per-protocol and intention-to-treat 510 
analyses implies that this did not introduce a bias to the trial. In addition, some children were lost 511 
to follow up. Multiple imputation was used to reduce the impact of these missing data under the 512 
missing at random assumption. However even with multiple imputation the results could be 513 
influenced by the selective follow-up of participants. Children who performed poorly at 2 years 514 
were more likely to be lost to follow up at 5 years. The reason for this is unclear however this is 515 
unlikely to lead to a bias as the 2 year outcome was included in the multiple imputation model. 516 
Overall, the loss to follow up was greater than anticipated in the protocol, however the 517 
boundaries of the 95% confidence intervals fell within the predefined bounds of equivalence 518 
indicating that the precision of the results was adequate in spite of this greater than expected loss 519 
to follow up.  520 
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Given the nature of the interventions it was impossible to mask the treating surgeons or 521 
anaesthetists to group allocation. It was also impractical to completely mask inquisitive parents 522 
as adhesives used to secure the airway usually leave signs of skin irritation in the general 523 
anaesthesia group, and there would be a puncture mark in the back from the spinal needle in the 524 
spinal group. Clinicians making the 5-year assessment were masked successfully in the great 525 
majority of cases. It is unlikely that unmasking surgeons, anaesthetists or parents would bias the 526 
outcome for the individually administered tests. However, when interpreting parent reported 527 
outcomes this potential bias should be considered.  528 
There are considerations to make when assessing the generalisability of the GAS trial. Firstly, 529 
the population was predominantly male, which was expected given the surgical pathology 530 
selected to create homogeneity within the study sample. Secondly, the infants were exposed over 531 
a narrow period of development (early infancy); this period being chosen as the period of high 532 
cerebral vulnerability and because this is when both awake regional anaesthesia and general 533 
anaesthesia are commonly used for herniorraphy. When determining at which age children might 534 
be at greatest risk, it is difficult to translate the animal data to humans.
13,43
  In general, younger 535 
animals have been found to be at greater risk and thus it would be expected that in humans, 536 
infants and the foetus would be most at risk. Some cohort studies have found children exposed at 537 
2-4 years of age to be at greater risk, but this may also be explained by confounding factors, and 538 
is less consistent with the preclinical data.
31,32
 Thirdly it could be argued that 5 years of age is 539 
too early to detect long term neurocognitive outcomes as there are a number of executive 540 
functions and social-emotional skills that do not develop until later in life.  However these results 541 
on individually administered, standardized tests and parent reports indicate that children who 542 
undergo anaesthesia in infancy start school life with no neurodevelopmental risk factors.  543 
Exploration of executive function and social emotional functions later in development could be 544 
an area of future study. Fifthly, in this trial the children received only one general anaesthetic 545 
(sevoflurane) in the general anaesthesia group. There are several other general anaesthetics that 546 
are used in childhood such as isoflurane, desflurane and propofol. At this stage there are no 547 
preclinical data to suggest that any effects seen with sevoflurane would be different to the effects 548 
seen with these other agents and thus it is reasonable to assume that the GAS trial results would 549 
translate to other general anaesthetic agents. There are also some preclinical data that suggest the 550 
effect may be greater if multiple agents are given concurrently. The GAS trial results cannot be 551 
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generalized to situations where multiple general anaesthetic agents are given concurrently.  552 
Lastly, the length of exposure was on average just under an hour and less than 2 hours for all 553 
children. Animal data suggest longer exposures are more likely to cause neurotoxicity, although 554 
there is no clear “cut off” for length of exposure that does or does not have an effect. While an 555 
hour of anaesthesia was shorter than the exposure used in many of the animal experiments, the 556 
equivalence of animal exposure time to that in humans is unknown. Furthermore the median 557 
duration of general anaesthesia for children in the 1.5 million procedures in the National 558 
Anesthesia Clinical Outcomes Registry (USA) was 57 minutes with infants having a median 559 
duration of 79 minutes.
44
  Thus the duration of exposure in the GAS trial is longer than nearly 560 
half the anaesthetics given to small children.  561 
The number of children potentially affected by national safety warnings about the neurotoxic 562 
potential of general anaesthesia such as the FDA warning is significant.  During the first 3 years 563 
of life approximately 10 percent of children from developed countries will undergo a general 564 
anaesthetic for a variety of surgical, diagnostic and medical procedures which translates to 565 
millions of children/year.
27,45
    Most of these children are healthy and will be exposed to a single 566 
short or intermediate length anaesthetic during their childhood.
40
  Given the high prevalence of 567 
exposure in early childhood, even small effects on brain development due to general anaesthesia 568 
could have very large public health consequences.   There is also the very real potential that 569 
parents and providers will delay necessary procedures in children in an effort to limit exposure at 570 
a time of cerebral vulnerability, putting some children at risk for both medical and 571 
developmental impairments.  The GAS trial, being consistent with data from in addition to 572 
several previous cohort studies, provides strong evidence that just under one hour of general 573 
anaesthesia in infancy does not cause significant neurocognitive or behavioural deficits.    574 
(Word count 5451) 575 
  576 
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Data sharing statement 577 
The de-identified data set collected for this analysis of the GAS trial will be available six months 578 
after publication of this manuscript. The study protocol, analysis plan and consent forms will 579 
also be available. The data may be obtained from the Murdoch Children’s Research Institute by 580 
emailing andrew.davidson@rch.org.au. Prior to releasing any data the following are required: a 581 
data access agreement must be signed between relevant parties, the GAS Trial Steering 582 
Committee must see and approve the analysis plan describing how the data will be analysed , 583 
there must be an agreement around appropriate  acknowledgement and any additional costs 584 
involved must be covered. Data will only be shared with a recognised research institution which 585 
has approved the proposed analysis plan.  586 
  587 
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 588 
Figure 1: Trial Profile 589 
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    Randomisation Follow-up - complete case*   
  Site 
RA,  
N = 361 
GA,  
N = 358 
PP - RA,  
N = 205 
PP - GA,  
N = 242 
ITT - RA, 
N = 251 
ITT - GA, 
N = 242   
  Australia               
  Royal Children's Hospital, Melbourne 57 28 39 44 46 44   
  Monash Medical Centre, Melbourne 26 25 15 15 16 15   
  Women's and Children's Hospital, Adelaide 6 5 2 3 4 3   
  Princess Margaret Hospital for Children, Perth 16 15 7 10 8 10   
  New Zealand               
  Starship Children's Hospital, Auckland 13 12 7 9 8 9   
  USA               
  Children's Hospital, Boston 29 31 18 21 22 21   
  Children's Memorial Hospital, Chicago 2 3 0 0 0 0   
  Dartmouth Hitchcock Medical Centre, Lebanon 2 2 2 1 2 1   
  Vanderbilt Children's Hospital, Nashville 1 2 0 1 0 1   
  The University of Iowa Hospital, Iowa 8 8 4 4 6 4   
  Children's Medical Centre, Dallas 7 7 0 7 2 7   
  Children's Hospital of Philadelphia, Philadelphia 1 1 0 1 0 1   
  Seattle Children's Hospital, Seattle 11 14 5 13 8 13   
  The Children's Hospital, Colorado 9 9 4 4 5 4   
  
The University of Vermont/ Fletcher Allen Health 
Care, Burlington 1 0 1 0 1 0   
  Canada               
  Montreal Children's Hospital, Montreal 21 20 9 15 11 15   
  Centre de Recherche CHU Sainte-Justine, Montreal 3 5 1 5 3 5   
  United Kingdom               
  Bristol Royal Hospital for Children, Bristol 2 2 1 1 1 1   
  Royal Hospital for Children, Glasgow 27 25 20 16 21 16   
  
Birmingham Children's Hospital NHS trust, 
Birmingham 7 6 5 3 6 3   
  Royal Belfast Hospital for Sick Children, Belfast 2 2 1 0 1 0   
  Royal Liverpool Children's Hospital, Liverpool 1 1 0 1 0 1   
  Sheffield Children's Hospital, Sheffield 5 4 0 1 3 1   
  Italy               
  Gaslini Hospital for Children, Genoa 42 39 23 26 30 26   
  Buzzi Children's Hospital, Milan 25 23 16 15 20 15   
  Ospedali Riunti, Bergamo 16 20 6 9 7 9   
  The Netherlands               
  
Wilhelmina Children's Hospital, University Medical 
Centre, Utrecht 15 14 14 13 14 13   
  Universitair Medish Centrum, Groningen 6 5 5 4 6 4   
  
RA = awake-regional anaesthesia. GA = general anaesthesia. PP = per protocol. ITT = intention to treat. *Complete 
case includes a full WPPSI-III assessed at 5 year follow-up. Results do not include partial assessments.    
  Table 1: Enrolment and complete case follow-up by site       
 590 
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    As per protocol Intention to treat   
    RA group, N = 287 GA group, N = 356 RA group, N = 361 GA group, N = 358   
  Baseline demographics           
  Gender, Male 232 (287, 81%) 304 (356, 85%) 294 (360, 82%) 306 (358, 86%)   
  
Chronological age at surgery (days)  287, 68·9 (31) 356, 71·1 (32) 358, 70·1 (32) 357, 71·0 (32) 
  
  
Post menstrual age at surgery (days) 287, 317·2 (32) 356, 319·7 (32) 357, 318·3 (33) 357, 319·5 (32) 
  
  Weight of child at surgery (kg)  287, 4·2 (1·1) 356, 4·3 (1·1) 359, 4·2 (1·1) 357, 4·3 (1·1)   
  Pregnancy and birth details            
  
Mean (SD) Post menstrual age at birth (days) 287, 248·2 (29) 356, 248·6 (27) 360, 248·3 (29) 358, 248·6 (27) 
  
  
Prematurity (Born < 37 weeks gestation) 160 (287, 56%) 195 (356, 55%) 198 (361, 55%) 196 (358, 55%) 
  
  Birth Weight (kg)  287, 2·3 (0·9) 355, 2·3 (0·9) 359, 2·4 (0·9) 357, 2·3 (0·9)   
  Z score for birth weight  287, -0·7 (1·3) 355, 0·7 (1·3) 359, -0·7 (1·2) 357, -0·7 (1·3)   
  
N, Median (IQR) Apgar score at 1 minute 237, 9 (7-9) 282,8·5 (7-9) 292, 9 (7-9) 284, 9 (7-9) 
  
  
N, Median (IQR)  Apgar score at 5 minutes 237, 9 (9-10) 282, 9 (9-10) 292, 9 (9-10) 284, 9 (9-10) 
  
  One of a multiple pregnancy 52 (284, 18%) 61 (356, 17%) 62 (360, 17%) 62 (358, 17%)   
  
Mother received partial course antenatal steroids 16 (287, 6%) 19 (356, 5%) 20 (360, 6%) 19 (358, 5%) 
  
  
Mother received complete course antenatal steroids 95 (287, 33%) 98 (356, 28%) 114 (360, 32%) 98 (358, 28%) 
  
  
Mother diagnosed with chorioamnionitis 10 (287, 4%) 12 (356, 3%) 11 (360, 3%) 12 (358, 3%) 
  
  
Prolonged rupture of the membranes (>24 hours) 28 (287, 10%) 34 (356, 10%) 32 (360, 9%) 34 (358, 10%) 
  
  
Mother diagnosed with pre-eclampsia 50 (287, 17%) 68 (356, 19%) 60 (360, 17%) 68 (358, 19%) 
  
  Sepsis during pregnancy  36 (286, 13%) 50 (356, 14%) 43 (358, 12%) 50 (358, 14%)   
  Mode of delivery of birth       
  Cephalic vaginal 135 (287, 47%) 157 (356, 44%) 169 (360, 47%) 157 (358, 44%)   
  Breech vaginal 1 (287, <1%) 6 (356, 2%) 3 (360, 1%) 6 (358, 2%)   
  Compound vaginal 2 (287, 1%) 4 (356, 1%) 3 (360, 1%) 4 (358, 1%)   
  Caesarean section 149 (287, 52%) 189 (356, 53%) 185 (360, 51%) 191 (358, 53%)   
  
Caesarean section and mother went into labour 42 (287, 15%) 58 (356, 16%) 52 (360, 14%) 59 (358, 16%) 
  
  
Mother exposed to nitrous oxide during delivery 48 (275, 18%) 62 (344, 18%) 61 (344, 18%) 62 (346, 18%) 
  
  IVH 7 (286, 2%) 6 (356, 2%) 8 (359, 2%) 6 (358, 2%)   
  IVH Grade 1 5 (286, 2%) 6 (356, 2%) 5 (359, 2%) 6 (358, 2%)    
  IVH Grade 2 2 (286, 1%) 0 (356) 2 (359, 1%) 0 (358)   
  Retinopathy of prematurity 17 (198, 9%) 16 (256, 6%) 20 (246, 8%) 16 (257, 6%)   
  
Hearing defects detected by perinatal screening 7 (253, 3%) 10 (356, 3%) 8 (316, 3%) 10 (325, 3%) 
  
   PDA diagnosed  23 (286, 8%) 21 (355, 6%) 27 (359, 8%) 21 (357, 6%)   
  PDA never treated 9 (286, 3%) 9 (355, 3%) 11 (359, 3%) 9 (357, 3%)   
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PDA treated with non-steroidal anti-inflammatory 
drugs 
14 (286, 5%) 10 (355, 3%) 16 (359, 4%) 10 (357, 3%) 
  
  Familial Demographics:           
  
Primary language(s) only spoken* 252 (287, 88%) 305 (356, 86%) 311 (360, 86%) 307 (358, 86%) 
  
   Maternal Age at Birth >21 273 (286, 96%) 339 (356, 95%) 339 (358, 95%) 341 (358, 95%)   
  
Family structure two caregivers together, at birth  261 (286, 91%) 324 (356, 91%) 328 (359, 91%) 326 (358, 91%) 
  
  Maternal education       
  Completed tertiary studies 150 (286, 52%) 171 (354, 48%) 181 (359, 51%) 171 (358, 48%)   
  Continuing tertiary studies 50 (286, 17%) 67 (354, 19%) 68 (359, 19%) 67 (358, 19%)   
  Completed year 11 or 12 62 (286, 22%) 83 (354, 23%) 77 (359, 22%) 84 (358, 24%)   
  Did not complete year 11 25 (286, 9%) 33 (354, 9%) 32 (359, 9%) 34 (358, 10%)   
  Anaesthesia  Details:           
  
N, Median (IQR)Blood glucose level (mmol/L) 255, 5·4 (4·7-6·1) 314, 5·5 (4·8-6·4) 312, 5·4 (4·7-6·2) 314, 5·5 (4·8-6·4) 
  
  Rescue glucose given IV 2 (282, 1%) 4 (356, 1%) 2 (350, 1%) 4 (356, 1%)   
  Haemoglobin (g/100 ml) 250, 10·3 (2·1) 307, 10·2 (2·0) 305, 10·3 (2·1) 307, 10·2 (2·0)   
  
Need for fluid bolus for hypotension 15 (287, 5%) 59 (356, 17%) 21 (355, 6%) 59 (356, 17%) 
  
  
Vasoactive drugs given (including atropine) 4 (287, 1%) 17 (356, 5%) 6 (355, 2%) 17 (356, 5%) 
  
  
N, Median (IQR)Duration of surgery (mins)  
286, 26·0 (19·0-
35·0) 
355, 28·0 (20·0-
40·0) 
353, 28·0 (20·0-
38·0) 
355, 28·0 (20·0-
40·0)   
  
N, Median (IQR) Duration of sevoflurane exposure 
(mins) 
NA 
356, 54·0 (41·0-
70·0) 
67, 42·0 (31·0-
62·5)** 
356, 54·0 (41·0-
70·0)   
  
Mean end tidal sevoflurane concentration (%)  NA 356, 2·6 (0·7) 67, 2·3 (0·8)** 356, 2·6 (0·7) 
  
  Total concentration x hours of exposure NA 356, 2·6 (1·1) 67, 1·9 (1·0)** 356, 2·6 (1·1)   
  
Any significant apnoea to 12hrs postop*** 6 (287, 2%) 15 (356, 4%) 10 (360, 3%) 15 (358, 4%) 
  
  
Data are n (N, % of non-missing data) or n, mean (SD), unless otherwise stated. APP= As Per Protocol; GA= General 
Anaesthesia; ITT= Intention to treat; IV= Intra-venously; IVH= Intra ventricular haemorrhage; IQR= Interquartile 
Range; PDA = Patent ductus arteriosus; RA= Awake Regional Anaesthesia.  
* The primary language spoken at home, is the primary language in each country that the Bayley was conducted eg. in 
Italy it was conducted in Italian 
** For those cases that received sevoflurane 
*** significant apnoea defined as a pause in breathing for more than 15 seconds  or more than 10 seconds if 
associated with oxygen saturation less than 80% or bradycardia (20% decrease in heart rate) 
  
    
    
  Table 2: Baseline descriptive statistics demographic data         
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    As per protocol Intention to treat   
  
  RA group, N = 287 GA group, N = 356 RA group, N = 361 GA group, N = 358 
  
  Assessment Details           
  
Location of 5-year assessment at 
hospital  198 (216, 91·7%) 228 (257, 88·7%) 246 (268, 91·8%) 228 (257, 88·7%)   
  Family Demographics at 5 years           
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Paid Employment is the main family 
income 201 (214, 93·9%) 237 (256, 92·6%) 243 (266, 91·4%) 237 (256, 92·6%)   
  
Family Structure, two caregivers living 
together 194 (214, 90·7%) 223 (257, 86·8%) 230 (266, 86·5%) 223 (257, 86·8%)   
  Number of children at home 
    
  
       1 50 (214, 23·4%) 53 (257, 20·6%) 63 (266, 23·7%) 53 (257, 20·6%)   
       2 95 (214, 44·4%) 133 (257, 51·8%) 120 (266, 45·1%) 133 (257, 51·8%)   
       3 56 (214, 26·2%) 48 (257, 18·7%) 67 (266, 25·2%) 48 (257, 18·7%)   
    > 3 13 (214, 6·1%) 23 (257, 8·9%) 16 (266, 6·0%) 23 (257, 8·9%)   
  Birth order 
    
  
      1 113 (211, 53·6%) 137 (257, 53·3%) 137 (261, 52·5%) 137 (257, 53·3%)   
      2 69 (211, 32·7%) 81 (257, 31·5%) 87 (261, 33·3%) 81 (257, 31·5%)   
   > 2 29 (211, 13·7%) 39 (257, 15·2%) 37 (261, 14·2%) 39 (257, 15·2%)   
  Age at follow-up assessment 217, 5·2 (0·2) 258, 5·3 (0·3) 269, 5·2 (0·2) 258, 5·3 (0·3)   
  Events since original anaesthesia         
  Any hospitalisation 101 (199, 50·8%) 129 (250, 51·6%) 131 (249, 52·6%) 129 (250, 51·6%)   
  Number of days hospitalised       
  0 105 (169, 62·1%) 127 (213, 59·6%) 125 (213, 58·7%) 127 (213, 59·6%)   
  1 22 (169, 13·0%) 30 (213, 14·1%) 34 (213, 16·0%) 30 (213, 14·1%)   
  2 11 (169, 6·5%) 13 (213, 6·1%) 13 (213, 6·1%) 13 (213, 6·1%)   
  >=3 31 (169, 18·3%) 43 (213, 20·2%) 41 (213, 19·2%) 43 (213, 20·2%)   
  Any anaesthesia  71 (102, 69·6%) 71 (111, 64·0%) 89 (133, 66·9%) 71 (111, 64·0%)   
  Number of anaesthetics 
    
  
  0 104 (156, 66·7%) 132 (181, 72·9%) 131 (197, 66·5%) 134 (183, 73·2%)   
  1 28 (156, 17·9%) 27 (181, 14·9%) 37 (197, 18·8%) 27 (183, 14·8%)   
  2 11 (156, 7·1%) 11 (181, 6·1%) 14 (197, 7·1%) 11 (183, 6·0%)   
  >=3 13 (156, 8·3%) 11 (181, 6·1%) 15 (197, 7·6%) 11 (183, 6·0%)   
  Any seizures 14 (173, 8·1%) 17 (217, 7·8%) 17 (217, 7·8%) 17 (217, 7·8%)   
  Events since 2 year assessment           
  
Child had a head injury that involved 
loss of consciousness  2 (213, 0·9%) 2 (266, 0·8%) 3 (265, 1·1%) 2 (257, 0·8%)   
  Child has any chronic illness 38 (213, 17·8%) 43 (258, 16·7%) 48 (265, 18·1%) 43 (258, 16·7%)   
  
Child had any prescribed medication for 
two months or longer  37 (214, 17·3%) 44 (257, 17·1%) 44 (266, 16·5%) 44 (257, 17·1%)   
  
Child has had an intervention for 
neurodevelopmental issues  49 (213, 23·0%) 60 (257, 23·3%) 64 (264, 24·2%) 60 (257, 23·3%)   
  Speech Therapy 36 (217, 16·6%) 48 (259, 18·5%) 50 (269, 18·6%) 48 (259, 18·5%)   
  Physiotherapy 11 (217, 5·1%) 17 (259, 6·6%) 12 (269, 4·5%) 17 (259, 6·6%)   
  Occupational Therapy 18 (217, 8·3%) 20 (259, 7·7%) 21 (269, 7·8%) 20 (259, 7·7%)   
  Psychology 7 (217, 3·2%) 6 (259, 2·3%) 8 (269, 3·0%) 6 (259, 2·3%)   
  Other interventions 9 (217, 4·1%) 16 (259, 6·2%) 12 (269, 4·5%) 16 (259, 6·2%)   
  
Child attends play group/child care on a 
regular basis 186 (213, 87·3%) 231 (257, 89·9%) 234 (265, 88·3%) 231 (257, 89·9%)   
  Physical examination             
  Height (cm)  207, 110·8 (5·5) 237, 110·8 (5·5) 254, 110·8 (5·4) 237, 110·8 (5·5)   
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  Weight (kg)  206, 19·3 (3·3) 236, 19·4 (2·8) 253, 19·4 (3·2) 236, 19·4 (2·8)   
  Head circumference (cm) 194, 51·6 (1·8) 224, 51·2 (2·6) 241, 51·6 (1·8) 224, 51·2 (2·6)   
  Arm circumference (cm)  191, 17·6 (1·9) 219, 17·4 (1·7) 233, 17·6 (1·9) 219, 17·4 (1·7)   
  
Data are n (N, % of non-missing data) or n, mean (SD). RA = awake-regional anaesthesia. GA = general anaesthesia. 
  
    
    
  Table 3: 5-year descriptive statistics data         
 592 
 593 
 594 
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APP multiple imputation APP complete case ITT multiple imputation ITT complete case 
    RA group GA group 
Difference in 
RA-GA* RA group GA group 
Difference in 
RA-GA* RA group GA group 
Difference in 
RA-GA* RA group GA group 
Difference in 
RA-GA*   
  Global function                           
  
WPPSI III - FSIQ composite 
score 
287, 99·1 
(18·4) 
356, 99.0 
(19·7) 
0·2 (-2·6; 
3·1) 
205, 100·5 
(14·3) 
242, 100·1 
(15·3) 
0·6 (-2·1; 
3·3) 
361, 98·9 
(18·0) 
358, 98·8 
(19·2) 
0·2 (-2·5; 
2·8) 
251, 100·4 
(14·1) 
242, 100·1 
(15·3) 
·266 (-2·3; 
2·8)   
  Verbal/language 
            
  
  
WPPSI- III Verbal IQ 
composite score 
287, 100·6 
(18·3) 
356, 99·7 
(20·4) 
0·8 (-2·1; 
3·8) 
206, 101·8 
(14·7) 
240, 100·9 
(15·4) 
0·7 (-2·1; 
3·4) 
361, 99·6 
(18·6) 
358, 99·6 
(19·1) 
0·0 (-2·6; 
2·7) 
251, 101·2 
(14·8) 
240, 100·9 
(15·4) 
0·0 (-2·6; 
2·5)   
  
NEPSY-II Word Generation 
scaled score 
287, 9·1 
(4·7) 
356, 9·0 
(4·8) 
0·1 (-0·6; 
0·9) 
182, 9·4 
(3·4) 
199, 9·3 
(3·3) 
0·1 (-0·6; 
0·8) 
361, 9·1 
(5·5) 
358, 9·1 
(4·7) 
-0·1 (0·6; 
0·5) 
220, 9·3 
(3·5) 
199, 9·3 
(3·3) 0.1 (-0·6; 0·7)   
  
NEPSY-II Speeded Naming 
combined scaled score 
287, 10·6 
(19·6) 
356, 7·4 
(23·9) 
3·3 (-1·1; 
7·7) 
132, 9·7 
(3·0) 
142, 9·8 
(3·2) 
0·0 (-0·7; 
0·8) 
361, 8·7 
(10·3) 
358, 9·2 
(15·0) 
-0·5 (-4·9; 
3·9) 
162, 9·8 
(3·0) 
142, 9·8 
(3·2) 
0·1 (-0·6; 
0·8)   
  Perceptual/visuo-spatial                           
  
WPPSI-III Performance IQ 
composite score 
287, 99·6 
(19·3) 
356, 100·0 
(20·3) 
-0·2 (-3·1; 
2·8) 
206, 100·7 
(15·2) 
241, 101·2 
(15·9) 
0·0 (-2·9; 
2·8) 
361, 100·1 
(18·2) 
358, 99·8 
(19·6) 
0·4 (-2·3;  
3·1) 
252, 101·1 
(14·7) 
241, 101·2 
(15·2) 
0·199 (-2·4; 
2·8)   
  
NEPSY-II Design Copy scaled 
score 
287, 9·4 
(23·8) 
356, 6·7 
(45·1) 
3·1 (-2·7;  
8·9) 
172, 9·6 
(3·4) 
207, 9·9 
(3·1) 
-0.2 (-0·8; 
0·5) 
361, 13·7 
(44·8) 
358, 9·6 
(26·1) 
3·9 (-2·6; 
10·4) 
212, 9·6 
(3·3) 
207, 9·9 
(3·1) 
-0·2 (-0·8; 
0·4)   
  Processing speed 
            
  
  
WPPSI-III Processing Speed Q 
composite score 
287, 95·2 
(20·8) 
356, 94·7 
(21·3) 
0·8 (-2·5;  
4·0) 
196, 95·8 
(14·5) 
220, 96·3 
(15·4) 
0·0 (-2·8; 
2·9) 
361, 95·8 
(20·5) 
358, 94·6 
(21·1) 
1·31 (-1·7;  
4·3) 
241, 96·3 
(14·4) 
220, 96·3 
(15·4) 
0·3 (-2·4; 
2·9)   
  Attention/executive function                           
  
NEPSY-II Sentence Repetition 
scaled score 
287, 6·4 
(29·7) 
356, 8·3 
(24·2) 
-1·4 (-5·4;  
2·7) 
175, 9·7 
(2·9) 
202, 9·7 
(2·8) 
0·0 (-0·6; 
0·6) 
361, 13·5 
(55·3) 
358, 10·8 
(23·3) 
2·4 (-1·0;  
5·8) 
214, 9·7 
(3.0) 
202, 9·7 
(2·8) 
-0·1 (-0·6; 
0·5)   
  
NEPSY-II Auditory Attention 
combined scaled score 
287, 8·7 
(4·3) 
356, 8·8 
(4·6) 
-0·1 (-0·8;  
0·6) 
167, 9·0 
(2·7) 
183, 9·3 
(3·0) 
-0·3 (-0·8; 
0·3) 
361, 8·7 
(4·2) 
358, 8·8 
(5·1) 
-0·1 (-0·8;  
0·6) 
207, 8·9 
(3·0) 
183, 9·3 
(3·0) 
-0·3 (-0·8; 
0·3)   
  
NEPSY-II Inhibition combined 
scaled score 
287, 7·9 
(6·0) 
356, 8·4 
(5·5) 
-0·5 (-1·3;  
0·3) 
150, 8·3 
(3·1) 
160, 8·9 
(3·0) 
-0·6 (-1·3; 
0·1) 
361, 7·8 
(7·2) 
358, 8·4 
(5·1) 
-0·6 (-1·5;  
0·4) 
179, 8·4 
(3·1) 
160, 8·9 
(3·0) 
-0·5 (-1·1; 
0·2)   
  NEPSY-II Statue scaled score 
287, 8·6 
(33·0) 
356, 10·8 
(32·1) 
-2·6 (-8·9;  
3·8) 
160, 8·8 
(3·5) 
182, 8·6 
(3·6) 
0·2 (-0·5; 
1·0) 
361, 7·1 
(19·3) 
358, 8·1 
(14·0) 
-0·9 (-1·7; -
0·2) 
192, 8·8 
(3·5) 
182, 8·6 
(3·6) 
0·2 (-0·5; 
0·9)   
  CMS Numbers scaled score 
287, 8·0 
(4·6) 
356, 7·8 
(4·6) 
0·2 (-0·5;  
0·9) 
194, 8·3 
(3·2) 
229, 8·1 
(3·4) 
0·1 (-0·5; 
0·7) 
361, 7·9 
(3·9) 
358, 7·7 
(4·3) 
0·1 (-0·5;  
0·8) 
236, 8·2 
(3·2) 
229, 8·1 
(3·4) 
0·0 (-0·6; 
0·6)   
  Memory & learning 
            
  
  
NEPSY-II Memory for Names 
combined scaled score 
287, 8·1 
(4·6) 
356, 8·0 
(4·6) 
0·2 (-0·5;  
0·9) 
180, 8·1 
(3·2) 
208, 8·1 
(3·2) 
0·2 (-0·5; 
0·8) 
361, 8·2 
(4·4) 
358, 8·0 
(4·6) 
0·2 (-0·5;  
0·9) 
218, 8·2 
(3·2) 
208, 8·1 
(3·2) 
0·2 (-0·4; 
0·8)   
  
CMS Word Lists I Learning 
scaled score 287, 8 (4·8) 
356, 8·3 
(4·9) 
-0·4 (-1·1;  
0·4) 
186, 8·3 
(3·4) 
224, 8·6 
(3·5) 
-0·4 (-1·0; 
0·3) 
361, 8·1 
(4·9) 
358, 8·3 
(5·3) 
-0·3 (-1·0;  
0·5) 
227, 8·3 
(3·4) 
224, 8·6 
(3·5) 
-0·3 (-1·0; 
0·3)   
  
CMS Word Lists  II Delayed 
scaled score 
287, 9·5 
(4·0) 
356, 9·4 
(4·4) 
0·1 (-0·5;  
0·8) 
178, 9·7 
(2·8) 
209, 9·6 
(2·9) 
0·0 (-0·5; 
0·6) 
361, 9·5 
(3·9) 
358, 9·3 
(4·7) 
0·1 (-0·5;  
0·7) 
216, 9·6 
(2·9) 
209, 9·6 
(2·9) 
0·0 (-0·6; 
0·5)   
  Social perception                           
  
NEPSY-II Affect Recognition 
scaled score 
287, 10·1 
(28·6) 
356, 8·9 
(18·1) 
1·5 (-1·7;  
4·6) 
174, 10·6 
(2·8) 
208, 10·4 
(3·2) 
0·3 (-0·4; 
0·9) 
361, 11·6 
(15·4) 
358, 7·4 
(74·2) 
4·3 (-5·0; 
13·5) 
215, 10·6 
(2·8) 
208, 10·4 
(3·2) 
0·2 (-0·3; 
0·8)   
  
NEPSY-II Theory of Mind 
scaled score 
287, 9·3 
(4·1) 
356, 9·6 
(4·6) 
-0·3 (-0·9;  
0·4) 
163, 9·8 
(2·9) 
178, 9·8 
(3·0) 
-0·1 (-0·7; 
0·5) 
361, 9·2 
(4·6) 
358, 9·6 
(4·3) 
-0·4 (-1·1;  
0·3) 
197, 9·7 
(3·1) 
178, 9·8 
(3·1) 
-0·2 (-0·8; 
0·4)   
  Sensorimotor 
            
  
  
NEPSY-II Fingertip Tapping 
Repetitions combined scaled 
score 
287, 9·5 
(5·4) 
356, 9·4 
(5·2) 
0.0 (-0·8;  
0·8) 
180, 9·8 
(3·4) 
195, 9·7 
(3·4) 
-0·1 (-0·8; 
0·5) 
361, 9·6 
(4·7) 
358, 9·5 
(5·3) 
0·1 (-0·6;  
0·9) 
217, 9·8 
(3·4) 
195, 9·7 
(3·4) 
0·0 (-0·6; 
0·6)   
  NEPSY-II Fingertip Tapping 287, 7·6 356, 7·1 0·5 (-0·4;  173, 8·1 183, 7·7 0·4 (-0·3; 361, 7·8 358, 7·2 0·6 (-0·4;  204, 8·1 183, 7·7 0·5 (-0·2;   
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Sequences combined scaled 
score 
(5·3) (6·6) 1·4) (3·4) (3·6) 1·1) (6·2) (6·2) 1·6) (3·4) (3·6) 1·1) 
  Academic                           
  
WIAT-II Word Reading 
composite score 
220, 92·1 
(20·5) 
275, 93·3 
(25·9) -1 (-4·5; 2·5) 
147, 92·3 
(18·1) 
167, 92·8 
(21·1) 
-1·5 (-4·7; 
1·8) 
278, 92·1 
(23·7) 
276, 93·3 
(26·6) 
-1·2 (-4·6;  
2·3) 
175, 92·8 
(18·8) 
167, 92·8 
(21·1) 
-1·3 (-4·4; 
1·8)   
  
WIAT-II Spelling composite 
score 
220, 90·2 
(16·3) 
275, 91·1 
(20·6) 
-1·2 (-3·6;  
1·2) 
141, 90·1 
(13·2) 
152, 90·8 
(16·5) 
-1·7 (-4·3; 
0·9) 
278, 89·9 
(17·8) 
276, 91·3 
(19·2) 
-1·6 (-4·2;  
1·1) 
166, 90·6 
(13·7) 
152, 90·8 
(16·5) 
-1·5 (-4·0; 
1·0)   
  
WIAT-II Numerical Operations 
composite score 
220, 98·0 
(21·3) 
275, 96·1 
(26·5) 
0·8 (-2·8;  
4·5) 
146, 98·8 
(16·2) 
161, 96·2 
(20·8) 
0·3 (-3·1; 
3·7) 
278, 97·1 
(20·8) 
276, 96·3 
(26·4) 
0·5 (-2·9;  
3·9) 
172, 98·7 
(16·6) 
161, 96·2 
(20·8) 
0·2 (-3·0; 
3·5)   
 
Data are n, mean (SD). *Difference (95%CI). RA = awake-regional anaesthesia. GA = general anaesthesia. SE = standard error. APP = as per protocol. ITT = intention to treat.  
  Table 4: Descriptive statistics WPPSI-III and other individually administered tests for each group             
 
    APP multiple imputation APP complete case ITT multiple imputation ITT complete case   
    RA group GA group 
Difference in 
RA-GA* RA group GA group 
Difference in 
RA-GA*  RA group GA group 
Difference in 
RA-GA*  RA group GA group 
Difference in 
RA-GA*    
  Executive function                           
  
BRIEF-P (Global 
Executive 
composite, T score) 
287, 49·2 
(16·0) 
356, 51·9 
(17·6) -2·7 (-5·2; -0·1) 
198, 48·4 
(12·5) 
232, 51·5 
(13·4) -2·9 (-5·4; -0·4) 
361, 49·6 
(15·5) 
358, 51·9 
(17·5) -2·4 (-4·8;  0·1) 
246, 48·9 
(12·7) 
232, 51·5 
(13·4) -2·4 (-4·7; 0·0) 
  
Adaptive 
Behaviour 
            
  
  
ABAS-2 (Global 
Adaptive Behaviour 
composite score) 
287, 94·4 
(20·9) 
356, 92·6 
(23·3) 2·0 (-1·2;  5·2) 
168, 95·9 
(16·3) 
200, 94·1 
(16·5) 1·5 (-1·7; 4·8) 
361, 94·3 
(23·3) 
358, 92·5 
(23·9) 1·9 (-1·3;  5·1) 
205, 95·5 
(16·8) 
200, 94·1 
(16·5) 1·0 (-2·1; 4·2)   
  
Maladaptive 
Behaviour                           
  
CBCL (Total 
problems, T score) 
287, 45·2 
(13·8) 
356, 47·1 
(16·6) -2·0 (-4·3;  0·4) 
215, 44·6 
(11·7) 
254, 46·7 
(12·5) -1·9 (-4·1; 0·3) 
361, 45·7 
(15·0) 
358, 47·1 
(15·6) -1·4 (-3·6;  0·8) 
265, 45 
(12·1) 
254, 46·7 
(12·5) -1·5 (-3·6; 0·6)   
  
CBCL (Internalising 
problems T score) 
287, 46·6 
(14·4) 
356, 48·5 
(17·4) -1·9 (-4·3;  0·6) 
215, 46·1 
(12·5) 
254, 48·0 
(12·5) -1·8 (-4·1; 0·4) 
361, 46·8 
(15·2) 
358, 48·5 
(16·0) -1·6 (-3·9;  0·6) 
265, 46·2 
(12·5) 
254, 48·0 
(12·5) -1·7 (-3·9; 0·4)   
  
CBCL 
(Externalising 
problems T score) 
287, 44·5 
(13·2) 
356, 46·1 
(15·0) -1·6 (-3·7;  0·5) 
215, 44·0 
(10·7) 
254, 45·8 
(11·9) -1·7 (-3·7; 0·4) 
361, 45·1 
(13·9) 
358, 46·1 
(15·0) -1·1 (-3·1;  1·0) 
265, 44·4 
(11·3) 
254, 45·8 
(11·9) -1·2 (-3·2; 0·8)   
  
Data are n, mean (SD). *Difference (95%CI).  RA = awake-regional anaesthesia. GA = general anaesthesia. SE = standard error. APP = as per protocol. ITT = intention to treat. 
  
    
    
  Table 5: Descriptive statistics parent-rated behavioural outcome measures by group               
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    As per protocol Intention to treat   
  
  
RA group, 
N = 287 
GA group, 
N = 356 
RR (95% CI) 
RA group, 
N = 361 
GA group, 
N = 358 
RR (95% CI) 
  
  Any developmental issues 25 (12·3) 21 (8·8) 1·4 (0·8; 2·4) 33 (12·9) 21 (8·8) 1·5 (0·9; 2·5)   
  Speech or language issues / interventions 18 (8·4) 17 (6·6)   24 (9) 17 (6·6)     
  Psychomotor issues / interventions 8 (3·7) 6 (2·3)   9 (3·4) 6 (2·3)     
  Global developmental delay 2 (1) 0 (0)   4 (1·6) 0 (0)     
  Behavioural disorders (ADHD, ASD or ODD) 8 (3·8) 15 (6) 0·7 (0·3; 1·7) 13 (4·9) 15 (6) 0·99 (0·5; 2·0)   
  
Diagnosed with Attention Deficit Hyperactivity 
Disorder (ADHD) 3 (1·4) 4 (1·6)   7 (2·6) 4 (1·6)     
  Diagnosed with Autism Spectrum Disorder (ASD) 5 (2·4) 11 (4·4)   7 (2·7) 11 (4·4)     
  Hearing abnormality 8 (3·8) 11 (4·4) 0·9 (0·4; 2·2) 12 (4·5) 11 (4·4) 1·1 (0·5; 2·4)   
  Child has a hearing aid 0 (0) 3 (1·2) 
 
0 (0) 3 (1·2) 
 
  
  Visual defect of any type in either eye 21 (9·9) 31 (12·2) 0·8 (0·5; 1·3) 28 (10·6) 31 (12·1) 0·8 (0·5; 1·4)   
  Legally blind (<6/60 in both eyes) 0 (0) 0 (0)   0 (0) 0 (0)     
  Cerebral palsy 1 (0·5) 3 (1·2) 0·6 (0·1; 5·5) 1 (0·4) 3 (1·2) 0·4 (0·0; 3·8)   
  
Data are n (% of non-missing data). RR = Risk Ratio. RA = awake-regional anaesthesia. GA = general anaesthesia. 
  
    
    
  Table 6: 5-year non-psychometric outcome data         
 
 
 
  RA group* GA group* 
Difference in 
RA-GA 
95% CI for 
difference in RA-GA   
  Age at surgery (<=70 days)         
  APP multiple imputation 111, 98·7 (20·3) 155, 98·2 (19·7) 0·6 -4·1 to 5·3   
  APP complete case 77, 100·2 (15·1) 107, 99·6 (15·8) 1·0 -3·5 to 5·6   
  ITT multiple imputation 145, 97·9 (18·6) 155, 98·2 (19·6) -0·4 -4·8 to 3·9   
  ITT complete case 97, 99·6 (14·9) 107, 99·6 (15·8) 0·0 -4·2 to 4·2   
  Age at surgery (>70 days)         
  APP multiple imputation 176, 99·7 (17·0) 201, 99·6 (21·0) 0·3 -3·4 to 4·1   
  APP complete case 128, 100·7 (13·9) 135, 100·5 (14·9) 0·5 -2·9 to 4·0   
  ITT multiple imputation 213, 100·0 (17·1) 202, 99·6 (18·7) 0·7 -2·7 to 4·1   
  ITT complete case 152, 100·9 (13·5) 135, 100·5 (14·9) 0·5 -2·7 to 3·8   
  Australia           
  APP multiple imputation 87, 96·0 (16·7) 103, 97·2 (18·4) -1·2 -6·2 to 3·9   
  APP complete case 63, 97·7 (13) 72, 98·6 (15·1) -0·6 -5·4 to 4·3   
  ITT multiple imputation 105, 96·9 (18·3) 103, 96·8 (18·6) 0·1 -5·2 to 5·3   
  ITT complete case 74, 98·4 (12·9) 72, 98·6 (15·1) 0·1 -4·5 to 4·6   
  USA           
  APP multiple imputation 49, 99·3 (18·9) 77, 99·6 (19·9) -0·6 -7·7 to 6·6   
  APP complete case 34, 101·2 (13·7) 52, 100·2 (16·0) 0·8 -5·6 to 7·2   
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  ITT multiple imputation 71, 98·1 (18·3) 77, 99·5 (18·9) -1·5 -7·7 to 4·7   
  ITT complete case 46, 100·2 (13·5) 52, 100·2 (16·0) -0·5 -6·3 to 5·3   
  Canada           
  APP multiple imputation 16, 93·4 (19·2) 25, 99·1 (19·2) -5·9 -19·7 to 8·0   
  APP complete case 10, 97 (12·5) 20, 100·1 (16·9) -3·8 -17·0 to 9·4   
  ITT multiple imputation 24, 94·7 (17·1) 25, 99·3 (18·6) -5·0 -15·4 to 5·5   
  ITT complete case 14, 95·9 (12·4) 20, 100·1 (16·9) -4·5 -15·5 to 6·4   
  New Zealand           
  APP multiple imputation 12, 89·5 (19·4) 12, 95·4 (18·5) -5·9 -23·3 to 11·5   
  APP complete case 7, 89·6 (13·2) 9, 96·8 (12·9) -9·9 -24·5 to 4·7   
  ITT multiple imputation 13, 90·5 (18·2) 12, 96·0 (17·6) -5·3 20·0 to 9·4   
  ITT complete case 8, 90·3 (12·4) 9, 96·8 (12·9) -8·5 -22·5 to 5·4   
  United Kingdom           
  APP multiple imputation 36, 97·8 (19·9) 39, 97·9 (20·1) 1·3 -7·3 to 10·0   
  APP complete case 27, 98·7 (18·4) 22, 100·1 (15.3) 2·8 -6·5 to 12·0   
  ITT multiple imputation 44, 96·9 (20·4) 40, 97·6 (20·9) -0·2 -8·6 to 8·3   
  ITT complete case 32, 97·8 (18·6) 22, 100·1 (15·3) 0·2 -8·8 to 9·2   
  Italy           
  APP multiple imputation 67, 107·3 (19·0) 81, 101·5 (21·4) 5·6 -1·0 to 12·3   
  APP complete case 45, 107·8 (12·5) 50, 103·1 (16·2) 4·7 -1·3 to 10·6   
  ITT multiple imputation 83, 106·5 (17·0) 82, 102·2 (20·9) 4·1 -1·7 to 9·9   
  ITT complete case 57, 107·2 (11·7) 50, 103·1 (16·2) 4·0 -1·4 to 9·4   
  The Netherlands           
  APP multiple imputation 20, 100·4 (13·4) 19, 99·1 (14·1) 1·3 -7·6 to 10·2   
  APP complete case 19, 100·3 (12·9) 17, 99·4 (10·3) 1·0 -6·9 to 9·0   
  ITT multiple imputation 21, 100·9 (13·2) 19, 98·9 (13·1) 2·0 -6·5 to 10·6   
  ITT complete case 20, 100·7 (12·7) 17, 99·4 (10·3) 1·5 -6·3 to 9·3   
  
*Data are n, M (SD). RA = awake-regional anaesthesia. GA = general anaesthesia. APP = as per protocol. 
ITT = intention to treat. Note: duration of surgery (< 2 hours vs >= 2 hours) subgroups were not done 
because all participants had surgery duration < 2 hours   
  Table 7: Subgroup analyses for the primary outcome (WPPSI III)       
 
 
    Attended 5 year visit Did not attend 5 year visit   
    
RA group,    
N = 271 
GA group,   
N = 259 Total, N = 530 
RA group,     
N = 90 
GA group,   
N = 99 Total, N = 189   
  Sex of child               
  Female 54 (19·9%) 36 (13·9%) 90 (17·0%) 12 (13·5%) 16 (16·2%) 28 (14·9%)   
  Male 217 (80·1%) 223 (86·1%) 440 (83·0%) 77 (86·5%) 83 (83·8%) 160 (85·1%)   
  Age (days) at surgery 67·1 (30·2) 71·9 (31·3) 69·5 (30·8) 79·1 (35·0) 68·7 (32·7) 73·6 (34·1)   
  Birth weight (kg) 2·4 (0·9) 2·3 (0·9) 2·4 (0·9) 2·2 (0·9) 2·3 (0·9) 2·3 (0·9)   
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  Maternal age at birth               
  >21 258 (95·2%) 252 (97·3%) 510 (96·2%) 81 (93·1%) 89 (89·9%) 170 (91·4%)   
  18-21 9 (3·3%) 6 (2·3%) 15 (2·8%) 2 (2·3%) 8 (8·1%) 10 (5·4%)   
  <18 4 (1·5%) 1 (0·4%) 5 (0·9%) 4 (4·6%) 2 (2·0%) 6 (3·2%)   
  PMA (days) at birth 249·5 (27·6) 248·4 (27·2) 249·0 (27·4) 244·6 (31·1) 249·0 (27·2) 246·9 (29·1)   
  Prematurity               
       >=37 121 (44·6%) 115 (44·4%) 236 (44·5%) 42 (46·7%) 47 (47·5%) 89 (47·1%)   
       <37 150 (55·4%) 144 (55·6%) 294 (55·5%) 48 (53·3%) 52 (52·5%) 100 (52·9%)   
  2-year Bayley-III scores               
  Cognitive scaled score 9·9 (2·7) 9·8 (3·0) 9·9 (2·8) 9·2 (3·4) 8·9 (2·6) 9·0 (3·0)   
  Language composite score  96·2 (14·7) 95·1 (16·0) 95·7 (15·3) 87·8 (17·0) 89·5 (13·3) 88·7 (15·1)   
  Motor composite score 98·5 (14·2) 97·2 (13·7) 97·9 (13·9) 94·1 (18·4) 96·0 (13·1) 95·1 (15·7)   
  Social-emotional scaled score 9·8 (3·8) 9·1 (3·6) 9·5 (3·8) 7·9 (3·5) 8·8 (3·7) 8·4 (3·6)   
  Attended the 2 year visit               
  No 55 (20·3%) 45 (17·4%) 100 (18·9%) 44 (48·9%) 43 (43·4%) 87 (46·0%)   
  Yes 216 (79·7%) 214 (82·6%) 430 (81·1%) 46 (51·1%) 56 (56·6%) 102 (54·0%)   
                  
  
Data are n (%) unless otherwise specified. RA = awake-regional anaesthesia. GA = general anaesthesia. PMA = 
postmenstrual age   
  
Table 8: Characteristics of children that attended the 5 year follow up are compared to the baseline data of 
the randomised population and the 2 year outcome data for those that attended the 2 year follow up.   
 
    As per protocol Intention to treat   
  
  
RA group,  
N = 287 
GA group,  
N = 356 
RA group,  
N = 361 
GA group,  
N = 358   
  
Psychologist discovered arm of the study the child was randomised to 7 (3.4%) 7 (2.9%) 11 (4.3%) 7 (2.9%) 
  
  
Paediatrician discovered arm of the study the child was randomised to 13 (8.0%) 13 (6.7%) 16 (7.9%) 13 (6.7%) 
  
  
Caregiver knew which arm of the study the child was randomised to 105 (51.2%) 118 (47.2%) 131 (51.4%) 118 (47.2%) 
  
  
Data are n (% of non-missing data). GA= General Anaesthesia; RA= Awake Regional Anaesthesia.  
  
    
  Table 9: Details of unmasking at 5 year assessment         
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